A form of cell communication called hedgehog signaling is vital for embryonic development in mammals. But aberrantly activated hedgehog signaling in multiple cancer types—including breast cancer—promotes tumor invasion, its spread to other organs and multi-drug resistance.
Two years ago, Lalita Shevde, Ph.D., and colleagues showed that hedgehog signaling plays a significant role in altering the immune components of the tumor microenvironment. Now they report how aberrant hedgehog signaling for tumor-associated macrophages—the immune cells that should be pro-inflammatory guardians against tumor growth—instead transforms them to nonaggressive, immunosuppressive macrophages, called M2 macrophages.
This signaling by the tumor microenvironment suggests that use of existing, clinically approved hedgehog-signaling inhibitors may diminish the tumor-promoting properties of tumor-associated M2 macrophages within the tumor microenvironment. Elevated infiltration of immunosuppressive, alternatively polarized M2 macrophages is associated with poor prognosis in cancer patients.
“The allure of targeting hedgehog signaling stems from the availability of several U.S. Food and Drug Administration-approved inhibitors already in use in the clinic, making it applicable to different tumor types,” said Shevde, a University of Alabama at Birmingham professor of pathology, who published her study in the journal Cancer Research. “Our work supports the possibility that hedgehog blockade is multi-dimensional in its effect on recalibrating the metabolism, and consequently, the functions of immunosuppressive macrophages.
“Thus, inhibition of hedgehog signaling could present with the dual benefit of directly targeting tumor cells and re-configuring the tumor immune microenvironment to an immune-activated state.”
M1 and M2 macrophages have distinct metabolic circuitries that contribute to their survival and different functions in the immune response. M1 macrophages have a metabolism that creates energy through glycolysis, which is sufficient for their tumor-eradicating functions, while M2 macrophages use oxidative phosphorylation, which is a much more efficient way to produce the energy needed for their tumor-promoting functions.
Using two mouse models of mammary tumors and treating them with the hedgehog inhibitor Vismodegib, Shevde and colleagues saw a remarkable shift in the tumor-infiltrating macrophages. The inhibitor significantly altered macrophage metabolism, especially reducing the flow through the uridine diphosphate N-acetylglucosamine biosynthetic pathway.
This, in turn, had a downstream effect on the transcription factor STAT6, decreasing its O-linked-N-acetylglucosaminylation (O-GlcNAc) modification, making it more active, which led to increased expression of genes Arg1 and Cd206 that are crucial for the immune-suppressive state of M2 macrophages. Upregulated STAT6 activity also led to increased expression of genes that shift the metabolism to fatty acid oxidation for the metabolically demanding M2 macrophages.
However, when the hedgehog inhibitor led to reduced O-GlcNAc-modification of STAT6, the macrophage metabolism and bioenergetics shifted from oxidative phosphorylation and fatty acid oxidation to glycolysis. Mitochondria—the powerhouses of the cell—changed from the fused mitochondria typical of cells utilizing fatty acid oxidation, to fragmented mitochondria.
“These hedgehog-inhibited macrophages are reminiscent of inflammatory M1 macrophages, phenotypically characterized by fragmented mitochondria,” Shevde said. “This is the first time that hedgehog activity has been shown to regulate metabolic and bioenergetic programming of tumor-associated macrophages. Further, our work provides evidence for modulating hedgehog activity, and consequently macrophage metabolism, to sculpt the plasticity of macrophages.”
Source: Read Full Article